Candesartan cilexetil (BioDeep_00001867997)
Main id: BioDeep_00000002546
代谢物信息卡片
Candesartan cilexetil
化学式: C33H34N6O6 (610.254)
中文名称: 坎地沙坦酯
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)OC(C)OC(=O)OC6CCCCC6
InChI: InChI=1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38)
描述信息
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist
D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
Candesartan Cilexetil (TCV-116) is an angiotensin II receptor inhibitor. Candesartan Cilexetil ameliorates the pulmonary fibrosis and has antiviral and skin wound healing effect. Candesartan Cilexetil can be used for the research of high blood pressure[1][2][3][4][5][6].
同义名列表
3 个代谢物同义名
数据库引用编号
13 个数据库交叉引用编号
- ChEBI: CHEBI:3348
- KEGG: C07709
- KEGGdrug: D00626
- PubChem: 2540
- DrugBank: DB00796
- ChEMBL: CHEMBL1014
- CAS: 1261393-19-4
- CAS: 145040-37-5
- PubChem: 9911
- NIKKAJI: J1.640.921I
- RefMet: Candesartan cilexetil
- medchemexpress: HY-17505
- KNApSAcK: 3348
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Mohammed Abdallah, Aysha Sayed Mohamed, Mina Ibrahim Tadros, Mohamed El-Nabarawi, Mai Ahmed Tawfik. Solusomes (novel soluplus® enriched nano-vesicular carriers) for improving the oral bioavailability of Candesartan cilexetil.
Pharmaceutical development and technology.
2023 Nov; ?(?):1-12. doi:
10.1080/10837450.2023.2289166. [PMID: 38014703] - Noha A T Abbas, Fawkia A Fayed, Rabab Saber El Sebaey, Heba A Hassan. Telmisartan and candesartan promote browning of white adipose tissue and reverse fatty liver changes in high fat diet fed male albino rats.
Naunyn-Schmiedeberg's archives of pharmacology.
2023 Oct; ?(?):. doi:
10.1007/s00210-023-02771-4. [PMID: 37831115] - Gustavo A Yerino, Ethel C Feleder, Emilia K Halabe, Liliana Diaz, Mario Sakson, Mariana Iglesias, Tobías Haddad, Emilio Roldán, Nélida Mondelo. Pharmacokinetics of a new fixed-dose combination of candesartan cilexetil, hydrochlorothiazide, and rosuvastatin in healthy adult subjects.
International journal of clinical pharmacology and therapeutics.
2022 Apr; 60(4):192-206. doi:
10.5414/cp204026. [PMID: 35103587] - Eui Hyun Jung, Chang-Keun Cho, Pureum Kang, Hye-Jung Park, Yun Jeong Lee, Jung-Woo Bae, Chang-Ik Choi, Choon-Gon Jang, Seok-Yong Lee. Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients.
Archives of pharmacal research.
2021 Dec; 44(12):1109-1119. doi:
10.1007/s12272-021-01363-1. [PMID: 34817825] - Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
Cell reports.
2021 04; 35(4):109040. doi:
10.1016/j.celrep.2021.109040. [PMID: 33910017] - Xin Chen, Xi Yang, Fei Mao, Jinlian Wei, Yixiang Xu, Baoli Li, Jin Zhu, Shuaishuai Ni, Lijun Jia, Jian Li. Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth invitro and invivo.
European journal of medicinal chemistry.
2021 Jan; 210(?):112964. doi:
10.1016/j.ejmech.2020.112964. [PMID: 33129593] - Shuaishuai Ni, Xin Chen, Qing Yu, Yixiang Xu, Zhiguo Hu, Junqian Zhang, Wenjuan Zhang, Baoli Li, Xi Yang, Fei Mao, Jing Huang, Yi Sun, Jian Li, Lijun Jia. Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
European journal of medicinal chemistry.
2020 Jan; 185(?):111848. doi:
10.1016/j.ejmech.2019.111848. [PMID: 31732254] - Usama Farghaly Aly, Hatem Abdel-Monsef Sarhan, Taha F S Ali, Hosny Abd El-Bakey Sharkawy. Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug.
Drug design, development and therapy.
2020; 14(?):1851-1865. doi:
10.2147/dddt.s248511. [PMID: 32523332] - Bryna S M Chow, Martina Kocan, Matthew Shen, Yan Wang, Lei Han, Jacqueline Y Chew, Chao Wang, Sanja Bosnyak, Katrina M Mirabito-Colafella, Giannie Barsha, Belinda Wigg, Elizabeth K M Johnstone, Mohammed A Hossain, Kevin D G Pfleger, Kate M Denton, Robert E Widdop, Roger J Summers, Ross A D Bathgate, Tim D Hewitson, Chrishan S Samuel. AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac Fibrosis.
Journal of the American Society of Nephrology : JASN.
2019 11; 30(11):2191-2207. doi:
10.1681/asn.2019060597. [PMID: 31511361] - Jasper Tromp, Li Shen, Pardeep S Jhund, Inder S Anand, Peter E Carson, Akshay S Desai, Christopher B Granger, Michel Komajda, Robert S McKelvie, Marc A Pfeffer, Scott D Solomon, Lars Køber, Karl Swedberg, Michael R Zile, Bertram Pitt, Carolyn S P Lam, John J V McMurray. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
Journal of the American College of Cardiology.
2019 08; 74(5):601-612. doi:
10.1016/j.jacc.2019.05.052. [PMID: 31370950] - Hafiz Awais Nawaz, Muhammad Irfan Masood, Mateen Abbas, Muhammad Usman, Abdul Muqeet Khan, Huma Rasheed, Sualeha Riffat. Evaluation of gender difference in pharmacokinetics of Candesartan cilexetil in the fasted state by RP-HPLC: A single dose comparative study.
Pakistan journal of pharmaceutical sciences.
2019 May; 32(3):1019-1024. doi:
NULL. [PMID: 31278715] - Takahiro Kanai, Kazuhiro Shiizaki, Hiroyuki Betsui, Jun Aoyagi, Takanori Yamagata. A decreased soluble Klotho level with normal eGFR, FGF23, serum phosphate, and FEP in an ADPKD patient with enlarged kidneys due to multiple cysts.
CEN case reports.
2018 11; 7(2):259-263. doi:
10.1007/s13730-018-0339-9. [PMID: 29767399] - Abdel Naser Zaid, Asma Radwan, Nidal Jaradat, Ayman Mousa, Nadia Ghazal, Rana Bustami. Formulation and In Vitro, In Vivo Correlation Between Two Candesartan Cilexetil Tablets.
Clinical pharmacology in drug development.
2018 08; 7(6):621-626. doi:
10.1002/cpdd.460. [PMID: 29746726] - Ahmed M Amer, Ahmed N Allam, Ossama Y Abdallah. Comparative Pharmaceutical Evaluation of Candesartan and Candesartan Cilexetil: Physicochemical Properties, In Vitro Dissolution and Ex Vivo In Vivo Studies.
AAPS PharmSciTech.
2018 Feb; 19(2):661-667. doi:
10.1208/s12249-017-0879-x. [PMID: 28948575] - Dan-Bee Park, Kyungho Jang, Jae-Won Lee, Cheol-Won Park, Back-Hwan Lee, Min-Gul Kim, Ji-Young Jeon. Pharmacokinetic and bioequivalence study comparing a candesartan cilexetil/rosuvastatin calcium fixed-dose combination with the concomitant administration of candesartan cilexetil and rosuvastatin calcium in healthy Korean subjects
.
International journal of clinical pharmacology and therapeutics.
2017 Mar; 55(3):286-294. doi:
10.5414/cp202740. [PMID: 28079517] - Narendar Dudhipala, Kishan Veerabrahma. Candesartan cilexetil loaded nanodelivery systems for improved oral bioavailability.
Therapeutic delivery.
2017 02; 8(2):79-88. doi:
10.4155/tde-2016-0063. [PMID: 28088883] - Anjan Paudel, Ameeduzzafar, Syed Sarim Imam, Mohd Fazil, Shahroz Khan, Abdul Hafeez, Farhan Jalees Ahmad, Asgar Ali. Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation.
Current drug delivery.
2017; 14(7):1005-1015. doi:
10.2174/1567201813666161230141717. [PMID: 28034361] - Timucin Ugurlu, Aysun Nalbantoglu, Ceyda Tuba Sengel-Turk. DEVELOPMENT OF SOLID LIPID NANOCARRIERS FOR ORAL DELIVERY OF CANDESERTAN CILEXETIL.
Acta poloniae pharmaceutica.
2016 Nov; 73(6):1631-1638. doi:
". [PMID: 29634119] - Narendar Dudhipala, Kishan Veerabrahma. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
Drug delivery.
2016; 23(2):395-404. doi:
10.3109/10717544.2014.914986. [PMID: 24865287] - Eiko Sunami, Koichi Nomura, Yutaka Nishiyama, Yasuo Katayama. Effects of Candesartan Cilexetil Compared with Amlodipine on Serum Asymmetric Dimethylarginine Levels in the Chronic Stage of Cerebral Infarction: A Preliminary Study.
Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.
2016; 83(6):272-276. doi:
10.1272/jnms.83.272. [PMID: 28133009] - Eliza Wolska, Anna Kluk, Magda Zarazińska, Magdalena Boniecka, Małgorzata Sznitowska. Choice of excipients for gelly-like pulp prepared ex tempore "on a spoon"- "placebo" and with sartans.
Drug development and industrial pharmacy.
2016; 42(6):998-1007. doi:
10.3109/03639045.2015.1103747. [PMID: 26548554] - Nilufer Yuksel, Zerrin Sezgin Bayindir, Elif Aksakal, A Tanju Ozcelikay. In situ niosome forming maltodextrin proniosomes of candesartan cilexetil: In vitro and in vivo evaluations.
International journal of biological macromolecules.
2016 Jan; 82(?):453-63. doi:
10.1016/j.ijbiomac.2015.10.019. [PMID: 26455402] - Norio Susa, Yayoi Nishida, Yoichi Yada, Tomohiro Nakayama, Satoshi Asai, Yasuo Takahashi. Comparative effect of fixed-dose combination tablets of candesartan cilexetil/amlodipine versus olmesartan medoxomil/azelnidipine on laboratory parameters in patients with hypertension: a retrospective cohort study.
Clinical and experimental hypertension (New York, N.Y. : 1993).
2016; 38(2):173-9. doi:
10.3109/10641963.2015.1081214. [PMID: 26453437] - Kaori Hayashi, Hiroyuki Sasamura, Mari Nakamura, Yusuke Sakamaki, Tatsuhiko Azegami, Hideyo Oguchi, Hirobumi Tokuyama, Shu Wakino, Koichi Hayashi, Hiroshi Itoh. Renin-angiotensin blockade resets podocyte epigenome through Kruppel-like Factor 4 and attenuates proteinuria.
Kidney international.
2015 Oct; 88(4):745-53. doi:
10.1038/ki.2015.178. [PMID: 26108068] - Surampalli Gurunath, Basavaraj K Nanjwade, P A Patil. Oral bioavailability and intestinal absorption of candesartan cilexetil: role of naringin as P-glycoprotein inhibitor.
Drug development and industrial pharmacy.
2015 Jan; 41(1):170-6. doi:
10.3109/03639045.2013.850716. [PMID: 24168234] - Dimitrios Ntountaniotis, Tahsin Kellici, Andreas Tzakos, Pinelopi Kolokotroni, Theodore Tselios, Johanna Becker-Baldus, Clemens Glaubitz, Sonyan Lin, Alexandros Makriyannis, Thomas Mavromoustakos. The application of solid-state NMR spectroscopy to study candesartan cilexetil (TCV-116) membrane interactions. Comparative study with the AT1R antagonist drug olmesartan.
Biochimica et biophysica acta.
2014 Oct; 1838(10):2439-50. doi:
10.1016/j.bbamem.2014.06.003. [PMID: 24946142] - Peter Bramlage, Hartmut Buhck, Claudia Zemmrich. Candesartan cilexetil 32 mg/hydrochlorothiazide 25 mg in unselected patients with high or very high cardiovascular risk: efficacy, safety, and metabolic impact.
Clinical drug investigation.
2014 Apr; 34(4):241-9. doi:
10.1007/s40261-014-0169-2. [PMID: 24482018] - Takuya Kishi, Yoshitaka Hirooka, Kenji Sunagawa. Telmisartan reduces mortality and left ventricular hypertrophy with sympathoinhibition in rats with hypertension and heart failure.
American journal of hypertension.
2014 Feb; 27(2):260-7. doi:
10.1093/ajh/hpt188. [PMID: 24096926] - Jadupati Malakar, Aalok Basu, Amit Kumar Nayak. Candesartan cilexetil microemulsions for transdermal delivery: formulation, in-vitro skin permeation and stability assessment.
Current drug delivery.
2014; 11(3):313-21. doi:
10.2174/1567201810666131211110517. [PMID: 24893994] - Yayoi Nishida, Yasuo Takahashi, Norio Susa, Nobukazu Kanou, Tomohiro Nakayama, Satoshi Asai. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Cardiovascular diabetology.
2013 Nov; 12(?):159. doi:
10.1186/1475-2840-12-159. [PMID: 24180232] - Tomoko Ishizuka, Yasushi Yoshigae, Nobuyuki Murayama, Takashi Izumi. Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1.
Drug metabolism and disposition: the biological fate of chemicals.
2013 Nov; 41(11):1888-95. doi:
10.1124/dmd.113.053595. [PMID: 23946449] - Ji-Young Jeon, Yong-jin Im, Yunjeong Kim, Su-mi Han, Myeong-jin Jo, Dae-Hee Shin, Ji-Seok Yoo, Byung-Kwan Moon, Byoung-Ki Kim, Byung-Hoon Lee, Yoon-Ho Choi, Beom-Sik Cho, Han-Young Jang, Soo-Wan Chae, Min-Gul Kim. Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers.
Drug development and industrial pharmacy.
2013 Sep; 39(9):1296-9. doi:
10.3109/03639045.2012.725732. [PMID: 23030309] - Zhiwen Zhang, Fang Gao, Shijun Jiang, Lingli Chen, Zeying Liu, Haijun Yu, Yaping Li. Bile salts enhance the intestinal absorption of lipophilic drug loaded lipid nanocarriers: mechanism and effect in rats.
International journal of pharmaceutics.
2013 Aug; 452(1-2):374-81. doi:
10.1016/j.ijpharm.2013.05.021. [PMID: 23694804] - Shinji Takai, Denan Jin, Hiroshi Sakonjo, Takayuki Takubo, Toyofumi Nakanishi. Significance of the vascular concentration of angiotensin II-receptor blockers on the mechanism of lowering blood pressure in spontaneously hypertensive rats.
Journal of pharmacological sciences.
2013; 123(4):371-9. doi:
10.1254/jphs.13167fp. [PMID: 24292382] - Raymond R Tjandrawinata, Effi Setiawati, Danang Agung Yunaidi, Ronal Simanjuntak, Iwan Dwi Santoso, Liana W Susanto. Bioequivalence study of two formulations of candesartan cilexetil tablet in healthy subjects under fasting conditions.
Drug design, development and therapy.
2013; 7(?):841-7. doi:
10.2147/dddt.s47272. [PMID: 23990709] - Charalambos Fotakis, Grigorios Megariotis, Dionysios Christodouleas, Eftichia Kritsi, Panagiotis Zoumpoulakis, Dimitrios Ntountaniotis, Maria Zervou, Constantinos Potamitis, Aden Hodzic, Georg Pabst, Michael Rappolt, Gregor Mali, Johanna Baldus, Clemens Glaubitz, Manthos G Papadopoulos, Antreas Afantitis, Georgia Melagraki, Thomas Mavromoustakos. Comparative study of the AT₁ receptor prodrug antagonist candesartan cilexetil with other sartans on the interactions with membrane bilayers.
Biochimica et biophysica acta.
2012 Dec; 1818(12):3107-20. doi:
10.1016/j.bbamem.2012.08.009. [PMID: 22906712] - Zhiwen Zhang, Fang Gao, Huihui Bu, Jisheng Xiao, Yaping Li. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats.
Nanomedicine : nanotechnology, biology, and medicine.
2012 Jul; 8(5):740-7. doi:
10.1016/j.nano.2011.08.016. [PMID: 21930110] - D Vijaya Bharathi, Kishore Kumar Hotha, Pankaj K Chatki, V Satyanarayana, V Venkateswarlu. LC-MS/MS method for simultaneous estimation of candesartan and hydrochlorothiazide in human plasma and its use in clinical pharmacokinetics.
Bioanalysis.
2012 Jun; 4(10):1195-204. doi:
10.4155/bio.12.83. [PMID: 22651563] - Tatsuhiko Azegami, Hiroyuki Sasamura, Kaori Hayashi, Hiroshi Itoh. Vaccination against the angiotensin type 1 receptor for the prevention of L-NAME-induced nephropathy.
Hypertension research : official journal of the Japanese Society of Hypertension.
2012 May; 35(5):492-9. doi:
10.1038/hr.2011.212. [PMID: 22158111] - Akiko Fujita, Keigyou Yoh, Homare Shimohata, Naoki Morito, Masami Ojima, Midori Okamura, Satoru Takahashi, Kunihiro Yamagata. A novel diabetes mellitus mouse model, MAFA-deficient and beta cell-specific MAFK-overexpressing hybrid transgenic mice, developed severe diabetic nephropathy and improved with TCV-116 (candesartan cilexetil) treatment.
Experimental animals.
2012; 61(1):49-57. doi:
10.1538/expanim.61.49. [PMID: 22293672] - Naokazu Hamada, Yoshihiro Nishi, Yuji Tajiri, Kentaro Setoyama, Ryozo Kamimura, Kenkichi Miyahara, Norihito Nuruki, Hiroshi Hosoda, Kenji Kangawa, Masayasu Kojima, Hiroharu Mifune. Disrupted regulation of ghrelin production under antihypertensive treatment in spontaneously hypertensive rats.
Circulation journal : official journal of the Japanese Circulation Society.
2012; 76(6):1423-9. doi:
10.1253/circj.cj-11-1345. [PMID: 22447011] - Waka Hayashi, Yoko Obata, Tomoya Nishino, Shinichi Abe, Kumiko Io, Akira Furusu, Katsushige Abe, Masanobu Miyazaki, Takeshi Sugaya, Takehiko Koji, Shigeru Kohno. Glomerular repair retardation via blocking of angiotensin II type 1a receptor pathway in a mouse glomerulonephritis model.
Nephron. Experimental nephrology.
2012; 122(1-2):13-22. doi:
10.1159/000346954. [PMID: 23446008] - Hae-Young Lee, Bum-Kee Hong, Wook Jin Chung, Byoung Kwon Lee, Seung Hwan Lee, Dong Woon Jeon, Young Keun Ahn, Dooil Kim, Chang Kyu Park, Sang-Hyun Kim, Hae Ok Jung, Byung-Ok Kim, Donghoon Choi. Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension.
Clinical therapeutics.
2011 Aug; 33(8):1043-56. doi:
10.1016/j.clinthera.2011.07.002. [PMID: 21831438] - Fang Gao, Zhiwen Zhang, Huihui Bu, Yan Huang, Zhiwei Gao, Jianan Shen, Chunjie Zhao, Yaping Li. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism.
Journal of controlled release : official journal of the Controlled Release Society.
2011 Jan; 149(2):168-74. doi:
10.1016/j.jconrel.2010.10.013. [PMID: 20951749] - Relu Cernes, Margarita Mashavi, Reuven Zimlichman. Differential clinical profile of candesartan compared to other angiotensin receptor blockers.
Vascular health and risk management.
2011; 7(?):749-59. doi:
10.2147/vhrm.s22591. [PMID: 22241949] - Thomas Philipp, Franck Martinez, Helmut Geiger, Bruno Moulin, Georges Mourad, Roland Schmieder, Michel Lièvre, Uwe Heemann, Christophe Legendre. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2010 Mar; 25(3):967-76. doi:
10.1093/ndt/gfp581. [PMID: 19887503] - Kai Lopau, Christoph Wanner. Hypertension after kidney transplantation: still a SECRET?.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2010 Mar; 25(3):664-5. doi:
10.1093/ndt/gfp712. [PMID: 20042402] - Emi Kamiyama, Daisuke Nakai, Tsuyoshi Mikkaichi, Noriko Okudaira, Osamu Okazaki. Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes.
Life sciences.
2010 Jan; 86(1-2):52-8. doi:
10.1016/j.lfs.2009.11.006. [PMID: 19914261] - Sheridan M Hoy, Gillian M Keating. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
2010; 10(5):335-42. doi:
10.2165/11206300-000000000-00000. [PMID: 20860416] - Reinhard Ketelhut, Peter Bramlage. Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.
Clinical drug investigation.
2010; 30(5):301-11. doi:
10.1007/bf03256905. [PMID: 20384386] - Veselin Mitrovic, Karl-Friedrich Appel, Nicolaos Proskynitopoulos, Seyfettin Dereli, Christian Wilhelm Hamm. Effects of candesartan cilexetil "add-on" treatment in congestive heart failure outpatients in daily practice.
Clinical research in cardiology : official journal of the German Cardiac Society.
2009 Jun; 98(6):379-89. doi:
10.1007/s00392-009-0011-7. [PMID: 19294444] - Amany Shweta, Luise A Cullen-McEwen, Michelle M Kett, Roger G Evans, Kate M Denton, Sharyn M Fitzgerald, Warwick P Anderson, John F Bertram. Glomerular surface area is normalized in mice born with a nephron deficit: no role for AT1 receptors.
American journal of physiology. Renal physiology.
2009 Mar; 296(3):F583-9. doi:
10.1152/ajprenal.90359.2008. [PMID: 19106212] - Egbert Godehard Schulz, Shadfar Bahri, Volker Schettler, Aron-Frederik Popov, Matthias Hermann. Pharmacokinetics and antihypertensive effects of candesartan cilexetil in patients undergoing haemodialysis: an open-label, single-centre study.
Clinical drug investigation.
2009; 29(11):713-9. doi:
10.2165/11319410-000000000-00000. [PMID: 19813774] - Tsuyoshi Yamane, Yoko Fujii, Kensuke Orito, Kaori Osamura, Takao Kanai, Yoshito Wakao. Comparison of the effects of candesartan cilexetil and enalapril maleate on right ventricular myocardial remodeling in dogs with experimentally induced pulmonary stenosis.
American journal of veterinary research.
2008 Dec; 69(12):1574-9. doi:
10.2460/ajvr.69.12.1574. [PMID: 19046003] - Terry C Major, Bronia Olszewski, Wendy Rosebury, Carlin Okerberg, Tage Carlson, Robert Ostroski, Richard Schroeder, Mark C Kowala, Robert Leadley. A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes.
Cardiovascular drugs and therapy.
2008 Dec; 22(6):469-78. doi:
10.1007/s10557-008-6131-x. [PMID: 18679781] - Yoshifuru Tamura, Masahiro Kosuga, Masahiro Yamashita, Satoru Tomioka, Michiko Sasaki, Tomoyuki Hikita, Hideaki Nakajima, Kenichiro Kojima, Shunya Uchida. Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4-5 chronic kidney disease.
Clinical and experimental nephrology.
2008 Aug; 12(4):256-263. doi:
10.1007/s10157-008-0040-y. [PMID: 18317875] - Tatsuo Hashimoto, Yoshiyuki Toya, Minoru Kihara, Machiko Yabana, Yoshiaki Inayama, Ken-Ichiro Tanaka, Kousaku Iwatsubo, Mai Yanagi, Jin Oshikawa, Toshiharu Kokuho, Tadashi Kuji, Shin-Ichiro Yoshida, Kouichi Tamura, Satoshi Umemura. Behçet's disease complicated by IgA nephropathy with nephrotic syndrome.
Clinical and experimental nephrology.
2008 Jun; 12(3):224-7. doi:
10.1007/s10157-008-0029-6. [PMID: 18224274] - Urara Mori-Takeyama, Shinya Minatoguchi, Ichijirou Murata, Hisayoshi Fujiwara, Yoko Ozaki, Michiya Ohno, Hiroshi Oda, Hiroshige Ohashi. Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis.
Clinical and experimental nephrology.
2008 Feb; 12(1):33-40. doi:
10.1007/s10157-007-0013-6. [PMID: 18175062] - P Bramlage, E Schönrock, P Odoj, W-P Wolf, C Funken. [Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZ].
MMW Fortschritte der Medizin.
2008 Jan; 149 Suppl 4(?):172-81. doi:
NULL. [PMID: 18402243] - Tetsuya Sugiyama, Takashi Okuno, Masayuki Fukuhara, Hidehiro Oku, Tsunehiko Ikeda, Hiroshi Obayashi, Mitsuhiro Ohta, Michiaki Fukui, Goji Hasegawa, Naoto Nakamura. Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes.
Experimental eye research.
2007 Sep; 85(3):406-12. doi:
10.1016/j.exer.2007.06.008. [PMID: 17678894] - Eduardo Podjarny, Joelle Bernheim, Galit Hasdan, Dorit Karsh, Gloria Rashid, Janice Green, Bernardo Katz, Jacques Bernheim. Additive renoprotective effect of candesartan and tetrahydrobiopterin in rats after 5/6 nephrectomy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2007 Jul; 22(7):1864-72. doi:
10.1093/ndt/gfm129. [PMID: 17442743] - Wilma Debernardi-Venon, Silvia Martini, Fiorella Biasi, Barbara Vizio, Angela Termine, Giuseppe Poli, Franco Brunello, Carlo Alessandria, Renato Bonardi, Giorgio Saracco, Mario Rizzetto, Alfredo Marzano. AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers.
Journal of hepatology.
2007 Jun; 46(6):1026-33. doi:
10.1016/j.jhep.2007.01.017. [PMID: 17336417] - Chiara M Meier, Giacomo D Simonetti, Silvia Ghiglia, Emilio Fossali, Patrizia Salice, Costanzo Limoni, Mario G Bianchetti. Palatability of angiotensin II antagonists among nephropathic children.
British journal of clinical pharmacology.
2007 May; 63(5):628-31. doi:
10.1111/j.1365-2125.2006.02814.x. [PMID: 17302913] - Kimiko Ishiguro, Hiroyuki Sasamura, Yusuke Sakamaki, Hiroshi Itoh, Takao Saruta. Developmental activity of the renin-angiotensin system during the "critical period" modulates later L-NAME-induced hypertension and renal injury.
Hypertension research : official journal of the Japanese Society of Hypertension.
2007 Jan; 30(1):63-75. doi:
10.1291/hypres.30.63. [PMID: 17460373] - Stefan Zorad, Jing-tao Dou, Julius Benicky, Daniel Hutanu, Katarina Tybitanclova, Jin Zhou, Juan M Saavedra. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma.
European journal of pharmacology.
2006 Dec; 552(1-3):112-22. doi:
10.1016/j.ejphar.2006.08.062. [PMID: 17064684] - M Saito, D Nakayama, M Takada, K Hirooka, Y Yasumura. Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil.
Journal of clinical pharmacy and therapeutics.
2006 Dec; 31(6):535-40. doi:
10.1111/j.1365-2710.2006.00772.x. [PMID: 17176359] - Fumiaki Yamashita, Hisakazu Ohtani, Noriko Koyabu, Fumihiko Ushigome, Hiroki Satoh, Hideyasu Murakami, Takeshi Uchiumi, Takanori Nakamura, Michihiko Kuwano, Masayuki Tsujimoto, Yasufumi Sawada. Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4.
The Journal of pharmacy and pharmacology.
2006 Nov; 58(11):1499-505. doi:
10.1211/jpp.58.11.0011. [PMID: 17132213] - Giacomo D Simonetti, Rodo O von Vigier, Martin Konrad, Mattia Rizzi, Emilio Fossali, Mario G Bianchetti. Candesartan cilexetil in children with hypertension or proteinuria: preliminary data.
Pediatric nephrology (Berlin, Germany).
2006 Oct; 21(10):1480-2. doi:
10.1007/s00467-006-0144-0. [PMID: 16802178] - Karlene Maitland, Lakeesha Bridges, Wendell P Davis, Joseph Loscalzo, Mildred A Pointer. Different effects of angiotensin receptor blockade on end-organ damage in salt-dependent and salt-independent hypertension.
Circulation.
2006 Aug; 114(9):905-11. doi:
10.1161/circulationaha.106.622316. [PMID: 16923758] - Hiroyuki Sasamura, Yudai Kitamura, Mari Nakamura, Munekazu Ryuzaki, Takao Saruta. Effects of the angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellular matrix metabolism in patients with essential hypertension.
Clinical and experimental hypertension (New York, N.Y. : 1993).
2006 Jul; 28(5):511-20. doi:
10.1080/10641960600798721. [PMID: 16820347] - Hidehisa Sasaki, Saburo Kanai, Tomokazu Oyama, Yoh Miyashita, Shigeo Yamamura, Kohji Shirai. Effect of combination therapy of benidipine hydrochloride and candesartan cilexetil on serum lipid metabolism and blood pressure in elderly hypertensive patients with type 2 diabetes mellitus.
Journal of atherosclerosis and thrombosis.
2006 Jun; 13(3):149-57. doi:
10.5551/jat.13.149. [PMID: 16835470] - Nathalie Sturm, Marie-Noëlle Hilleret, Thierry Dreyfus, Didier Barnoud, Vincent Leroy, Jean-Pierre Zarski. [Candesartan Cilexetil (Atacand) induced prolonged severe cholestasis improved by extracorporeal albumin dialysis].
Gastroenterologie clinique et biologique.
2005 Dec; 29(12):1299-301. doi:
10.1016/s0399-8320(05)82229-8. [PMID: 16518295] - Tsukasa Nakamura, Takeshi Sugaya, Yasuhiro Kawagoe, Yoshihiko Ueda, Shiwori Osada, Hikaru Koide. Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease.
The American journal of the medical sciences.
2005 Oct; 330(4):161-5. doi:
10.1097/00000441-200510000-00002. [PMID: 16234607] - Shuichi Tsuruoka, Michi Wakaumi, Takashi Ioka, Hisashi Yamamoto, Hitoshi Ando, Kohichi Sugimoto, Akio Fujimura. Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan.
British journal of clinical pharmacology.
2005 Aug; 60(2):204-7. doi:
10.1111/j.1365-2125.2005.02394.x. [PMID: 16042674] - Frank Pietruck, Gerhard Kiel, Manfred Birkel, Bodo Stahlheber-Dilg, Thomas Philipp. Evaluation of the effect of candesartan cilexetil on the steady-state pharmacokinetics of tacrolimus in renal transplant patients.
Biopharmaceutics & drug disposition.
2005 May; 26(4):135-41. doi:
10.1002/bdd.440. [PMID: 15768377] - Hiroaki Nakamura, Tatsuya Inoue, Naohisa Arakawa, Yuki Shimizu, Yasushi Yoshigae, Izumi Fujimori, Emi Shimakawa, Tohru Toyoshi, Tomihisa Yokoyama. Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models.
European journal of pharmacology.
2005 Apr; 512(2-3):239-46. doi:
10.1016/j.ejphar.2005.02.047. [PMID: 15840410] - Enrico Agabiti Rosei, Damiano Rizzoni, Maria Lorenza Muiesan, Intissar Sleiman, Massimo Salvetti, Cristina Monteduro, Enzo Porteri. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
Journal of hypertension.
2005 Feb; 23(2):435-44. doi:
10.1097/00004872-200502000-00027. [PMID: 15662233] - Rayaz A Malik, Ian J Schofield, Ashley Izzard, Clare Austin, Georgina Bermann, Anthony M Heagerty. Effects of angiotensin type-1 receptor antagonism on small artery function in patients with type 2 diabetes mellitus.
Hypertension (Dallas, Tex. : 1979).
2005 Feb; 45(2):264-9. doi:
10.1161/01.hyp.0000153305.50128.a1. [PMID: 15630048] - Sabine Leh, Øyvind Vaagnes, Solomon B Margolin, Bjarne M Iversen, Terje Forslund. Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2005 Jan; 20(1):71-82. doi:
10.1093/ndt/gfh562. [PMID: 15561744] - J M Willemsen, T J Rabelink, P Boer, C A Gaillard. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
Journal of human hypertension.
2004 Dec; 18(12):857-63. doi:
10.1038/sj.jhh.1001769. [PMID: 15361886] - K Homma, K Hayashi, T Kanda, K Yoshioka, I Takamatsu, S Tatematsu, H Kumagai, S Wakino, T Saruta. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
Journal of human hypertension.
2004 Dec; 18(12):879-84. doi:
10.1038/sj.jhh.1001761. [PMID: 15295613] - H Kakizawa, Y Itoh, S Imamura, T Matsumoto, Y Ishiwata, Y Ono, K Yamamoto, T Kato, N Hayakawa, N Oda, Y Goto, Y Goto, A Nagasaka, T Senda, M Itoh. Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
2004 Jul; 36(7):458-64. doi:
10.1055/s-2004-825725. [PMID: 15305228] - Michel Azizi, Alvine Bissery, Maxime Lamarre-Cliche, Joël Ménard. Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans.
Hypertension (Dallas, Tex. : 1979).
2004 Apr; 43(4):785-90. doi:
10.1161/01.hyp.0000125698.00128.64. [PMID: 15023936] - Akira Nishiyama, Masanori Yoshizumi, Matlubur Rahman, Hiroyuki Kobori, Dale M Seth, Akira Miyatake, Guo-Xing Zhang, Li Yao, Hirofumi Hitomi, Takatomi Shokoji, Hideyasu Kiyomoto, Shoji Kimura, Toshiaki Tamaki, Masakazu Kohno, Youichi Abe. Effects of AT1 receptor blockade on renal injury and mitogen-activated protein activity in Dahl salt-sensitive rats.
Kidney international.
2004 Mar; 65(3):972-81. doi:
10.1111/j.1523-1755.2004.00476.x. [PMID: 14871417] - Kazuya Omoto, Kazunari Tanabe, Tadahiko Tokumoto, Hiroaki Shimmura, Hideki Ishida, Hiroshi Toma. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.
Transplantation.
2003 Oct; 76(8):1170-4. doi:
10.1097/01.tp.0000073615.57523.ac. [PMID: 14578748] - Osamu Iimura, Eiji Kusano, Kaichiro Tanba, Satoru Yanagiba, Morimasa Amemiya, Yasuhiro Ando, Sumiko Honma, Shigeaki Muto, Yasushi Asano. [Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis].
Nihon Jinzo Gakkai shi.
2003 Jul; 45(5):439-44. doi:
. [PMID: 14509219] - Satoru Murayama, Tsutomu Hirano, Taro Sakaue, Kenta Okada, Reiko Ikejiri, Mitsuru Adachi. Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure.
Hypertension research : official journal of the Japanese Society of Hypertension.
2003 Jun; 26(6):453-8. doi:
10.1291/hypres.26.453. [PMID: 12862201] - Hisao Ando, Kazunori Furugori, Daijiro Shibata, Toko Harata, Yasutaka Murata, Shigehiko Mizutani. Dual renin-angiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome receiving IVF and elective embryo cryopreservation: a case series.
Human reproduction (Oxford, England).
2003 Jun; 18(6):1219-22. doi:
10.1093/humrep/deg268. [PMID: 12773449] - Giorgio Basile, Daniela Villari, Sebastiano Gangemi, Tiziana Ferrara, Maria G Accetta, Vittorio Nicita-Mauro. Candesartan cilexetil-induced severe hepatotoxicity.
Journal of clinical gastroenterology.
2003 Mar; 36(3):273-5. doi:
10.1097/00004836-200303000-00017. [PMID: 12590242] - V Mitrovic, R Willenbrock, M Miric, P Seferovic, J Spinar, M Dabrowski, W Kiowski, D S Marks, E Alegria, A Dukát, K Lenz, H A Arens. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
American heart journal.
2003 Mar; 145(3):E14. doi:
10.1067/mhj.2003.161. [PMID: 12660683] - Hiroaki Mukawa, Yukio Toki, Yutaka Miyazaki, Hideo Matsui, Kenji Okumura, Takayuki Ito. Angiotensin II type 2 receptor blockade partially negates antihypertrophic effects of type 1 receptor blockade on pressure-overload rat cardiac hypertrophy.
Hypertension research : official journal of the Japanese Society of Hypertension.
2003 Jan; 26(1):89-95. doi:
10.1291/hypres.26.89. [PMID: 12661917] - Francisco Fernández-Vega, José Abellán, Onofre Vegazo, Soledad García De Vinuesa, José Carlos Rodríguez, Benito Maceira, Saturnino Sanz de Castro, Roberto Robles Nicolás, José Luño. Angiotensin II type 1 receptor blockade to control blood pressure in postmenopausal women: influence of hormone replacement therapy.
Kidney international. Supplement.
2002 Dec; ?(82):S36-41. doi:
10.1046/j.1523-1755.62.s82.8.x. [PMID: 12410853] - Yasutaka Nagisa, Asae Shintani, Shizue Nakagawa. [Ameliorative effects on retinal disorder in diabetic SHRSP (stroke-prone spontaneously hypertensive rat)].
Nihon rinsho. Japanese journal of clinical medicine.
2002 Oct; 60(10):1975-80. doi:
. [PMID: 12397694] - Kiyoshi Kurokawa, Keishi Abe, Takao Saruta, Masaaki Arakawa, Ryuichi Kikkawa, Naohiko Ueda, Kaoru Onoyama, Kimio Tomita, Nobuya Ogawa. Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis.
Journal of the renin-angiotensin-aldosterone system : JRAAS.
2002 Sep; 3(3):167-75. doi:
10.3317/jraas.2002.037. [PMID: 12563567] - Hideaki Nakaya, Hiroyuki Sasamura, Mizuo Mifune, Ryoko Shimizu-Hirota, Mari Kuroda, Matsuhiko Hayashi, Takao Saruta. Prepubertal treatment with angiotensin receptor blocker causes partial attenuation of hypertension and renal damage in adult Dahl salt-sensitive rats.
Nephron.
2002 Aug; 91(4):710-8. doi:
10.1159/000065035. [PMID: 12138277] - Mitsuhide Naruse, Akiyo Tanabe, Atsuhisa Sato, Sachiko Takagi, Ken Tsuchiya, Toshihiro Imaki, Kazue Takano. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats.
Hypertension (Dallas, Tex. : 1979).
2002 Jul; 40(1):28-33. doi:
10.1161/01.hyp.0000022606.52221.2f. [PMID: 12105134] - Takanori Matsuo, Eiichiro Ishikawa, Masayuki Ohta, Yumiko Shibouta, Yoshimasa Ishimura, Yoshimi Imura, Yasuo Sugiyama. Renal protective effect of candesartan cilexetil in spontaneously hypercholesterolemic rats.
Japanese journal of pharmacology.
2002 Mar; 88(3):300-6. doi:
10.1254/jjp.88.300. [PMID: 11949885] - Jun Araya, Tetsuhiro Tsuruma, Koichi Hirata, Atsuhito Yagihashi, Naoki Watanabe. TCV-116, an angiotensin II type 1 receptor antagonist, reduces hepatic ischemia-reperfusion injury in rats.
Transplantation.
2002 Feb; 73(4):529-34. doi:
10.1097/00007890-200202270-00006. [PMID: 11889423] - Kohji Takara, Mikio Kakumoto, Yusuke Tanigawara, Junko Funakoshi, Toshiyuki Sakaeda, Katsuhiko Okumura. Interaction of digoxin with antihypertensive drugs via MDR1.
Life sciences.
2002 Feb; 70(13):1491-500. doi:
10.1016/s0024-3205(01)01494-1. [PMID: 11895100]
